Low versus standard dose mCPP challenge in obsessive-compulsive patients

Stefano Erzegovesi, Livia Martucci, Marta Henin, Laura Bellodi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In several reports, the acute oral administration of the partial serotonergic agonist meta-chlorophenylpiperazine (mCPP) in dose of 0.5 mg/kg induced a significant worsening of obsessive-compulsive (OC) symptoms in a number of patients. The aim of our study was to test the 0.25 mg/kg mCPP dose, which was hypothesized to be more specific for OC symptoms and was until now tested only on healthy subjects. In a double-blind, controlled crossover study, 12 OC patients participated on three test days, receiving one of the following on each day: oral 0.5 mg/kg mCPP (standard dose), 0.25 mg/kg mCPP (low dose), or placebo. Behavioral ratings were obtained by means of Visual Analogue Scale (VAS) ratings. The low dose mCPP induced a significant worsening of OC symptoms in 50% (6/12) of the patients, whereas 8.3% (1/12) of the patients showed a worsening after the standard dose. On the other hand, only the standard dose mCPP induced a worsening, although not statistically significant, of anxiety ratings. Our data show that the 0.25 mg/kg dose mCPP induces a specific response in OC symptoms, with little anxiogenic effect. To confirm these preliminary data, future studies will be needed on larger samples and with more sensitive rating scales. (C) 2000 American College of Neuropsychopharmacology.

Original languageEnglish
Pages (from-to)31-36
Number of pages6
JournalNeuropsychopharmacology
Volume24
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Serotonin Receptor Agonists
1-(3-chlorophenyl)piperazine
Visual Analog Scale
Cross-Over Studies
Oral Administration
Healthy Volunteers
Anxiety
Placebos

Keywords

  • Anxiety
  • Meta-chlorophenylpiperazine
  • Obsessive-compulsive disorder
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Low versus standard dose mCPP challenge in obsessive-compulsive patients. / Erzegovesi, Stefano; Martucci, Livia; Henin, Marta; Bellodi, Laura.

In: Neuropsychopharmacology, Vol. 24, No. 1, 2001, p. 31-36.

Research output: Contribution to journalArticle

Erzegovesi, Stefano ; Martucci, Livia ; Henin, Marta ; Bellodi, Laura. / Low versus standard dose mCPP challenge in obsessive-compulsive patients. In: Neuropsychopharmacology. 2001 ; Vol. 24, No. 1. pp. 31-36.
@article{2391b0b1b86348ad9fffd72a77c662b6,
title = "Low versus standard dose mCPP challenge in obsessive-compulsive patients",
abstract = "In several reports, the acute oral administration of the partial serotonergic agonist meta-chlorophenylpiperazine (mCPP) in dose of 0.5 mg/kg induced a significant worsening of obsessive-compulsive (OC) symptoms in a number of patients. The aim of our study was to test the 0.25 mg/kg mCPP dose, which was hypothesized to be more specific for OC symptoms and was until now tested only on healthy subjects. In a double-blind, controlled crossover study, 12 OC patients participated on three test days, receiving one of the following on each day: oral 0.5 mg/kg mCPP (standard dose), 0.25 mg/kg mCPP (low dose), or placebo. Behavioral ratings were obtained by means of Visual Analogue Scale (VAS) ratings. The low dose mCPP induced a significant worsening of OC symptoms in 50{\%} (6/12) of the patients, whereas 8.3{\%} (1/12) of the patients showed a worsening after the standard dose. On the other hand, only the standard dose mCPP induced a worsening, although not statistically significant, of anxiety ratings. Our data show that the 0.25 mg/kg dose mCPP induces a specific response in OC symptoms, with little anxiogenic effect. To confirm these preliminary data, future studies will be needed on larger samples and with more sensitive rating scales. (C) 2000 American College of Neuropsychopharmacology.",
keywords = "Anxiety, Meta-chlorophenylpiperazine, Obsessive-compulsive disorder, Serotonin",
author = "Stefano Erzegovesi and Livia Martucci and Marta Henin and Laura Bellodi",
year = "2001",
doi = "10.1016/S0893-133X(00)00178-0",
language = "English",
volume = "24",
pages = "31--36",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Low versus standard dose mCPP challenge in obsessive-compulsive patients

AU - Erzegovesi, Stefano

AU - Martucci, Livia

AU - Henin, Marta

AU - Bellodi, Laura

PY - 2001

Y1 - 2001

N2 - In several reports, the acute oral administration of the partial serotonergic agonist meta-chlorophenylpiperazine (mCPP) in dose of 0.5 mg/kg induced a significant worsening of obsessive-compulsive (OC) symptoms in a number of patients. The aim of our study was to test the 0.25 mg/kg mCPP dose, which was hypothesized to be more specific for OC symptoms and was until now tested only on healthy subjects. In a double-blind, controlled crossover study, 12 OC patients participated on three test days, receiving one of the following on each day: oral 0.5 mg/kg mCPP (standard dose), 0.25 mg/kg mCPP (low dose), or placebo. Behavioral ratings were obtained by means of Visual Analogue Scale (VAS) ratings. The low dose mCPP induced a significant worsening of OC symptoms in 50% (6/12) of the patients, whereas 8.3% (1/12) of the patients showed a worsening after the standard dose. On the other hand, only the standard dose mCPP induced a worsening, although not statistically significant, of anxiety ratings. Our data show that the 0.25 mg/kg dose mCPP induces a specific response in OC symptoms, with little anxiogenic effect. To confirm these preliminary data, future studies will be needed on larger samples and with more sensitive rating scales. (C) 2000 American College of Neuropsychopharmacology.

AB - In several reports, the acute oral administration of the partial serotonergic agonist meta-chlorophenylpiperazine (mCPP) in dose of 0.5 mg/kg induced a significant worsening of obsessive-compulsive (OC) symptoms in a number of patients. The aim of our study was to test the 0.25 mg/kg mCPP dose, which was hypothesized to be more specific for OC symptoms and was until now tested only on healthy subjects. In a double-blind, controlled crossover study, 12 OC patients participated on three test days, receiving one of the following on each day: oral 0.5 mg/kg mCPP (standard dose), 0.25 mg/kg mCPP (low dose), or placebo. Behavioral ratings were obtained by means of Visual Analogue Scale (VAS) ratings. The low dose mCPP induced a significant worsening of OC symptoms in 50% (6/12) of the patients, whereas 8.3% (1/12) of the patients showed a worsening after the standard dose. On the other hand, only the standard dose mCPP induced a worsening, although not statistically significant, of anxiety ratings. Our data show that the 0.25 mg/kg dose mCPP induces a specific response in OC symptoms, with little anxiogenic effect. To confirm these preliminary data, future studies will be needed on larger samples and with more sensitive rating scales. (C) 2000 American College of Neuropsychopharmacology.

KW - Anxiety

KW - Meta-chlorophenylpiperazine

KW - Obsessive-compulsive disorder

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0035213085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035213085&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(00)00178-0

DO - 10.1016/S0893-133X(00)00178-0

M3 - Article

VL - 24

SP - 31

EP - 36

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -